Literature DB >> 28603320

Impact of Triple Combinations of Retinoic Acid, Mold Spores and Citral on the F344 Rat Lung Tissue Pathology.

Ibrahim O Farah1, Carlene Holt-Gray1, Joseph A Cameron1, Michelle Tucci1, Zelma Cason1, Hamed Benghuzzi1.   

Abstract

The impact of retinoic acid (All Trans Retinoic Acid; ATRA) and Mold spores (MLD) in the development of lung pathology and in vivo tissue remodeling have not been well established in the literature. In addition, the role of citral (inhibitor of retinoid function) in the improvement of lung pathology has not been ascertained in animal studies. Therefore, it is hypothesized that ATRA and Mold (MLD) exposure will sensitize lung tissues leading to lung tissue pathology and that Citrals (C1 and C2) will reverse, ameliorate or improve the associated pathological damage to lung tissues. The study used an IACUC approved between-subject in vivo randomized split plot factorial design (F344 rat model; N=40). Animals were exposed to seven different treatments including untreated control, MLD, ATRA, Citrals (C1 and C2) and their MLD combinations (MLD+ ATRA+ C1, and MLD+ ATRA+ C2) by intra-peritoneal route. Rat weight and blood data were collected on Days 1 and 21, all animals were sacrificed on day 21, and lung tissues were processed for histopathology. Results from weight and blood data (ANOVA and Duncan) as well as from histopathological analyses supported the findings that exposure of F344 rats to MLD combinations with ATRA and Citrals showed various levels of lung tissue damage that were impacted by either C1 or C2 exposure. This promising study showed impressive responses on the interaction of MLD, Citrals, and ATRA as related to their impact on associated lung tissue pathologies.

Entities:  

Keywords:  ATRA; Chronic Lung Pathology; Citral; F344; Hpervitaminosis A; Mold Spores; Ovalbumin

Year:  2016        PMID: 28603320      PMCID: PMC5463610     

Source DB:  PubMed          Journal:  Biomed Sci Instrum        ISSN: 0067-8856


  32 in total

1.  Retinoid acid esterase activities: tissue and subcellular distribution in mice.

Authors:  C C Wang; D L Hill
Journal:  Biochem Pharmacol       Date:  1977-05-15       Impact factor: 5.858

2.  Retinoic acid treatment partially rescues failed septation in rats and in mice.

Authors:  G D Massaro; D Massaro
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-05       Impact factor: 5.464

Review 3.  Could bronchial asthma be an endogenous, pulmonary expression of retinoid intoxication?

Authors:  A R Mawson
Journal:  Front Biosci       Date:  2001-08-01

Review 4.  Steroids, retinoids, and wound healing.

Authors:  G M Anstead
Journal:  Adv Wound Care       Date:  1998-10       Impact factor: 4.730

Review 5.  Retinoids in lung development.

Authors:  F Chytil
Journal:  FASEB J       Date:  1996-07       Impact factor: 5.191

6.  Citral, an inhibitor of retinoic acid synthesis, attenuates the frequency and severity of branchial arch abnormalities induced by triazole-derivative fluconazole in rat embryos cultured in vitro.

Authors:  Francesca Di Renzo; Maria L Broccia; Erminio Giavini; Elena Menegola
Journal:  Reprod Toxicol       Date:  2007-08-07       Impact factor: 3.143

7.  Damp housing and childhood respiratory symptoms: the role of sensitization to dust mites and molds.

Authors:  A P Verhoeff; R T van Strien; J H van Wijnen; B Brunekreef
Journal:  Am J Epidemiol       Date:  1995-01-15       Impact factor: 4.897

8.  Developmental regulation of elastin production. Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state mRNA levels.

Authors:  M H Swee; W C Parks; R A Pierce
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

Review 9.  Indoor mold, toxigenic fungi, and Stachybotrys chartarum: infectious disease perspective.

Authors:  D M Kuhn; M A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

10.  Regulation of retinoic acid signaling during lung morphogenesis.

Authors:  S Malpel; C Mendelsohn; W V Cardoso
Journal:  Development       Date:  2000-07       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.